




MAPS
Public Benefit
Corporation

MDMA-Assisted Therapy for Treatment of PTSD

- **Mission-driven, patient-focused** organization formed in 2014 to advance the **clinical development** and **commercialization** of **novel mental health treatments**
- Lead program, **MDMA-assisted therapy (MDMA-AT)** for PTSD, is an **FDA-designated Breakthrough Therapy**
- **Two successful Phase 3 trials**, both of which met primary and secondary endpoints
- MDMA-AT program on track for **FDA approval and commercial launch in 2024**

PTSD Is Severe, Chronic & Costly^(a,b)



\$230bn+ Est. Annual Economic Burden
(Society, Healthcare, Families)^(c)

Current Treatments Are Limited

Psychotherapy

- ✗ Variable efficacy
- ✗ Challenging delivery
- ✗ High drop-out

Pharmacotherapy

- ✗ Limited efficacy
- ✗ Require chronic use
- ✗ Target symptoms only
- ✗ Side effects

56% of PTSD Patients Don't Recover
(Non-recovery rate at 40-months)^(d)

MPBC's Lead Program, MDMA-AT, Is A Potential Breakthrough Treatment for PTSD

Results from First Phase 3 (MAPP1)^(e)

67%

**Share of
Participants
Who Lost PTSD
Diagnosis**
Compared to 32%
in Control Group

88%

**Share of
Participants With
Clinically-Significant
Improvement**
Compared to 60%
in Control Group

Compelling Rationale for MDMA-AT

- ✓ Strong biological underpinning
- ✓ Addresses root cause
- ✓ Acute treatment
- ✓ Combines medicine and psychotherapy
- ✓ Efficacy in refractory patients
- ✓ Well-tolerated

Positive MAPP1 Results Published in Nature Medicine

Preparation Underway for Post-Approval Implementation of MDMA-AT



*Educate medical
field on MDMA-AT*



*Ensure providers are
ready to deliver care*



*Secure favorable
insurance coverage*



*Support clinic
readiness and adoption*

**Multiple Growth
Opportunities**

*Geographic
Expansion in PTSD*

*MDMA-AT
Indication Expansion*

*Development of
Other Molecules*

Sources: (a) VA National Center for PTSD. (b) Open Patient Level Claims Data 2017-2021. (c) Davis et al., The Economic Burden of Posttraumatic Stress Disorder in The United States From a Societal Perspective, J Clin Psychiatry, 2022. (d) Morina et al. Remission From Post-traumatic Stress Disorder In Adults: A Systematic Review and Meta-analysis of Long-Term Outcome Studies. Clin Psychol Rev. 2014 (n=8,641). (e) Mitchell et al., MDMA-Assisted Therapy For Severe PTSD: A Randomized, Double-blind, Placebo-controlled Phase 3 Study. Nat Med. 2021. Securities offered through Finalis Securities, LLC, Member FINRA and SIPC. finalis.com/disclaimers/